Can Vilazodone Offer New Hope for Parkinson's-Related Dyskinesia?
"Research suggests the antidepressant drug Vilazodone could reduce involuntary movements linked to Parkinson's treatment without compromising motor benefits."
Parkinson's disease, a neurodegenerative disorder affecting millions worldwide, is characterized by motor and non-motor symptoms that significantly impact quality of life. While there's no cure for Parkinson's, treatments like L-3,4-dihydroxyphenylalanine (L-DOPA) can help manage symptoms and improve motor function. However, long-term L-DOPA use often leads to a troubling side effect: L-DOPA-induced dyskinesia (LID).
LID manifests as abnormal, involuntary movements that can range from mild tics to debilitating writhing motions, severely impacting a patient's daily life and potentially outweighing the benefits of L-DOPA therapy. Researchers have been exploring various strategies to combat LID, with the serotonin system emerging as a key target. Many approaches targeting serotonin receptors or transporters have shown promise in animal models, but translating these findings into effective clinical treatments has proven challenging.
Now, a new study shines a spotlight on Vilazodone, an antidepressant drug already approved by the U.S. Food and Drug Administration (FDA), as a potential solution. Vilazodone stands out because it acts as both a selective serotonin reuptake inhibitor (SSRI) and a partial agonist of the 5-HT1A receptor, two mechanisms known to have antidyskinetic effects. This unique combination positions Vilazodone as a promising candidate for reducing LID without sacrificing the motor-improving benefits of L-DOPA.
The Growing Burden of Parkinson’s Disease
Parkinson’s disease is a common neurodegenerative disorder that severely affects quality of life. A 2026 study assesses its prevalence, incidence, mortality, and disability-adjusted life years from 1990 to 2021 across global, regional, national, and Socio-demographic Index levels. The Parkinson’s Foundation estimates that Parkinson’s-related direct and indirect costs approach $25 billion annually in the United States, while Parkinson’s disease organizations report that nearly 90,000 Americans are diagnosed each year.
Vilazodone: A Dual-Action Approach to Managing Dyskinesia
The study, published in the journal Movement Disorders, investigated Vilazodone's effects on L-DOPA-induced behaviors, neurochemistry, and gene expression in a rat model of Parkinson's disease. Researchers used unilateral 6-hydroxydopamine (6-OHDA)-lesioned hemi-parkinsonian rats, a common model for studying Parkinson's, to mimic the dopamine depletion seen in the disease. The rats were divided into groups and treated with L-DOPA, Vilazodone, or a combination of both over several weeks.
- Reduced Dyskinesia: Vilazodone effectively reduced abnormal involuntary movements (AIMs) in both L-DOPA-primed and L-DOPA-naive rats.
- Maintained Motor Function: Unlike some antidyskinetic drugs, Vilazodone did not compromise the beneficial effects of L-DOPA on motor function, as measured by the forepaw adjusting steps (FAS) task.
- Normalized Dopamine Kinetics: In the dopamine-depleted striatum, Vilazodone-L-DOPA cotreatment increased dopamine content, suggesting a normalization of dopamine kinetics in dyskinetic brain.
- Attenuated Gene Expression: Vilazodone reduced L-DOPA-induced overexpression of c-Fos and preprodynorphin mRNA, indicative of attenuated dopamine D1 receptor-mediated direct pathway overactivity.
- 5-HT1A Receptor Involvement: Blocking the 5-HT1A receptor partially attenuated Vilazodone's antidyskinetic efficacy, highlighting the importance of this receptor in Vilazodone's mechanism of action.
Limits of Current Dyskinesia Treatments
Levodopa-induced dyskinesia remains one of the most disabling complications of long-term dopaminergic therapy. The 2025 Frontiers review states that amantadine is the only established standard FDA-approved treatment, while istradefylline offers a complementary non-dopaminergic option. Continuous intrajejunal levodopa/carbidopa gel can reduce dyskinesias and improve motor fluctuations, but surgery and abdominal tubing may make it unsuitable for some patients, and the approach remained investigational in the United States according to the cited review.
Dyskinesia, Dystonia, and Treatment Options
Dyskinesia and dystonia are distinct movement problems in Parkinson’s disease, with differences in their symptoms, causes, and treatment approaches. Parkinson’s Foundation materials describe dyskinesias as involuntary, erratic movements usually caused by levodopa rather than by Parkinson’s disease itself; peak-dose and diphasic dyskinesia are common patterns. Comparisons of sarizotan with established treatments such as amantadine reflect the continuing search for effective pharmacological and surgical options for levodopa-induced dyskinesia.
A Promising Step Forward
These findings suggest that Vilazodone holds promise as a potential treatment for L-DOPA-induced dyskinesia in Parkinson's patients. By targeting both serotonin reuptake and 5-HT1A receptors, Vilazodone may offer a more comprehensive approach to managing LID than previous strategies. While further research is needed to confirm these findings in human clinical trials, the study provides a compelling rationale for repositioning Vilazodone as a valuable tool in the fight against Parkinson's-related dyskinesia, potentially improving the lives of countless individuals affected by this challenging condition.
Evidence Still Favors Individualized Management
A 2025 network-analysis report states that the optimal therapy for Parkinson’s disease dyskinesia has not been identified because of insufficient comparative evidence. In a post hoc analysis, patients receiving levodopa-carbidopa intestinal gel experienced significant improvements in dyskinesia, pain, and health-related outcomes at week 12 compared with optimized medical treatment. These findings support potential benefits for advanced Parkinson’s disease while underscoring that treatment decisions remain clinically complex.
Broadening the Parkinson’s Research Pipeline
Current reviews identify symptomatic and disease-modifying therapies as major areas of Parkinson’s research and call for priorities that advance understanding and treatment. Recent research updates highlight adaptive deep brain stimulation using BrainSense, Onapgo, VYALEV, tavapadon, prasinezumab, alpha-synuclein biomarkers, and GLP-1 trial results. Other emerging work includes vaccine strategies intended to intervene at earlier stages of disease and potentially slow progression while preserving function and independence.